BioCentury | Aug 22, 2020
Translation in Brief

IPD’s synthetic bio unlocks target combos for cell therapy; plus Merck’s oral STING agonist, Surrozen’s regenerative therapy and more

Synthetic switches aim T cells at cells expressing antigen combos David Baker’s team at University of Washington’s Institute for Protein Design published a study in Science showing its synthetic protein switches can direct T cells...
BioCentury | Jun 17, 2020
Deals

With Ideaya deal, GSK bulks up synthetic lethality side of oncology business

A deal with Ideaya gives GSK a path to growing its synthetic lethality pipeline, a corner of the pharma’s cancer rebuild still primarily centered around PARP inhibitor Zejula. On Tuesday, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and...
BioCentury | Jun 13, 2019
Tools & Techniques

GSK teams up with Doudna, Weissman labs to create CRISPR genomics center

GlaxoSmithKline’s latest move to reinvigorate R&D is a collaboration with two of the biggest names in CRISPR research to develop new gene editing technologies and use them to identify drug targets. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)...
BioCentury | Mar 29, 2019
Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
BioCentury | Oct 11, 2018
Distillery Therapeutics

Cancer

INDICATION: Basal cell carcinoma (BCC) Mouse studies suggest combining LGR5, LRP6 or PORCN inhibitors with Erivedge vismodegib could help treat BCC. In two mouse models of BCC, diphtheria toxin-mediated depletion of LGR5 decreased tumor burden...
BioCentury | May 24, 2018
Product R&D

Bias-less bispecifics

Taking a leaf from the small molecule playbook, cancer play Merus N.V. is bringing unbiased screening to the bispecifics space. The biotech is betting the approach can discover bispecific antibodies with novel activity against known...
BioCentury | May 2, 2018
Distillery Techniques

Chemistry; drug platforms

TECHNOLOGY: Tool compounds; structural analyses Structural analysis of a peptide inhibitor bound to the cysteine-rich domain (CRD) of FZD7 could guide the development of small molecule FZD7 inhibitors, and the peptide could be used to...
BioCentury | Feb 21, 2018
Distillery Therapeutics

Gastrointestinal

INDICATION: Gastrointestinal Patient sample and mouse studies identified a BBC3 inhibitor that could help treat intestinal injury caused by topoisomerase inhibitors for cancer. In mice receiving the generic topoisomerase inhibitor irinotecan, BBC3 knockout increased survival...
BioCentury | Jun 2, 2017
Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
BioCentury | May 11, 2017
Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
Items per page:
1 - 10 of 34